📊 BKYI Key Takeaways
Investment Thesis
BIO KEY INTERNATIONAL is in severe financial distress with negative operating cash flow of -$2.8M, deteriorating profitability (net margin of -59.1%), and declining revenue (-10.6% YoY). The company is cash-consuming with operating losses exceeding $2.6M despite maintaining a healthy 77.3% gross margin, indicating fundamental business model challenges beyond cost structure.
BKYI Strengths
- Strong gross margin of 77.3% suggests pricing power and product efficiency at the direct cost level
- Zero long-term debt eliminates refinancing and solvency risk in near term
- Adequate liquidity with current ratio of 1.26x and $2.0M cash provides runway for operations
BKYI Risks
- Negative operating cash flow of -$2.8M indicates the business is not self-sustaining and burning cash
- Revenue declining 10.6% YoY combined with widening operating losses suggests loss of market competitiveness
- Large gap between high gross margin and negative operating margin indicates severe operational inefficiency and high fixed costs relative to revenue base
- Negative ROE of -47.5% and ROA of -28.4% demonstrate poor capital utilization and shareholder value destruction
Key Metrics to Watch
- Operating cash flow trend and path to positive cash generation
- Revenue stabilization and return to growth trajectory
- Operating expense reduction relative to revenue base to achieve operating profitability
- Cash runway and adequacy of $2.0M in light of $2.8M annual cash burn rate
BKYI Financial Metrics
💡 AI Analyst Insight
BIO KEY INTERNATIONAL INC presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
BKYI Profitability Ratios
BKYI vs Technology Sector
How BIO KEY INTERNATIONAL INC compares to Technology sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BKYI Balance Sheet & Liquidity
BKYI 5-Year Financial Trend
5-Year Trend Summary: BIO KEY INTERNATIONAL INC's revenue has grown significantly by 173% over the 5-year period, indicating strong business expansion. The most recent EPS of $-3.04 indicates the company is currently unprofitable.
BKYI Growth Metrics (YoY)
BKYI Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.5M | -$510.3K | $-0.15 |
| Q2 2025 | $1.1M | -$510.3K | $-0.20 |
| Q1 2025 | $1.6M | -$510.3K | $-0.16 |
| Q3 2024 | $1.8M | -$510.3K | $-0.39 |
| Q2 2024 | $1.1M | -$510.3K | $-1.00 |
| Q1 2024 | $2.2M | -$510.3K | $-0.32 |
| Q3 2023 | $1.4M | -$288.3K | $-0.07 |
| Q2 2023 | $1.9M | -$288.3K | $-0.16 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BKYI Capital Allocation
BKYI SEC Filings
Access official SEC EDGAR filings for BIO KEY INTERNATIONAL INC (CIK: 0001019034)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BKYI
What is the AI rating for BKYI?
BIO KEY INTERNATIONAL INC (BKYI) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BKYI's key strengths?
Strong gross margin of 77.3% suggests pricing power and product efficiency at the direct cost level. Zero long-term debt eliminates refinancing and solvency risk in near term.
What are the risks of investing in BKYI?
Negative operating cash flow of -$2.8M indicates the business is not self-sustaining and burning cash. Revenue declining 10.6% YoY combined with widening operating losses suggests loss of market competitiveness.
What is BKYI's revenue and growth?
BIO KEY INTERNATIONAL INC reported revenue of $4.9M.
Does BKYI pay dividends?
BIO KEY INTERNATIONAL INC pays dividends, with $0.1M distributed to shareholders in the trailing twelve months.
Where can I find BKYI SEC filings?
Official SEC filings for BIO KEY INTERNATIONAL INC (CIK: 0001019034) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BKYI's EPS?
BIO KEY INTERNATIONAL INC has a diluted EPS of $-0.01.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.